[Link]
http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.113.003128/-/DC1
[Link]
http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.113.003128/-/DC1
[Link]
mailto:Malcolm.macleod@ed.ac.uk
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
[Link]
http://stroke.ahajournals.org/
563
Lacunar strokes are small subcortical strokes caused by 
occlusion of single penetrating arteries. Although thromboembolism
is a common cause of large artery stroke, the 
lacunar hypothesis,1 much debated,2,3 proposes that key mechanisms
in lacunar pathology are microatheroma and lipohyalinosis
, and that thromboembolic lacunar stroke is uncommon.4
Microatheroma are lipid-containing plaques, which are thought 
to accumulate in the parent main intracranial artery, such as 
the middle cerebral artery, and affect the origin of penetrating
arteries, or develop in the proximal-penetrating arterioles 
themselves. Lipohyalinosis is a small-vessel pathology characterized
by abnormal endothelial architecture and fibrosis, 
leading to thickening of the vessel wall and irregular luminal 
diameter.5 Despite associations with inflammatory endothelial 
dysfunction and blood–brain barrier disruption,3,6,7 the causes 
of these small-vessel changes are poorly understood.
Around 25% of all ischemic strokes are lacunar,8 and 
although they have an apparently good functional prognosis 
compared with cortical ischemic stroke, similar proportions of 
patients have poststroke cognitive impairment and long-term 
studies suggest that they identify cerebral small vessel disease 
(SVD), which puts patients at high risk of recurrent ischemic 
strokes9 and of cognitive decline.10,11
However, there is incomplete understanding of the precise
mechanisms that lead to the pathology described above, 
and current therapeutic strategies are limited. This occurs 
against a background of translational failure, where many 
interventions reported to improve outcome in animal models 
of ischemic stroke more generally are not effective in human 
clinical trial.12
It may be that animal models do not model human disease 
with sufficient validity to guide drug development; or that they 
do have this external validity but their conduct and reporting 
make them a poor guide, in practice, to support clinical drug 
development and trial design. For several animal models of 
neurological disease, systematic review and meta-analysis 
Background and Purpose—A total of 25% of strokes are lacunar, and these are pathophysiologically different from large 
artery strokes. Despite emerging evidence of a substantial impact on physical disability and dementia, little attention has 
been paid to the development of specific treatments. The optimal use of the animal models of lacunar stroke used to test 
candidate interventions is not known.
Methods—We conducted a systematic review and meta-analysis of studies testing candidate interventions in animal models 
of lacunar stroke. We used random-effects meta-analysis to assess the impact of study characteristics and trim and fill to 
seek evidence of publication bias.
Results—The efficacy of 43 distinct interventions was described in 57 publications. The median number of quality 
checklist items scored was 3 of 8 (interquartile range, 2–4). Many models reflected mechanisms of limited relevance 
to lacunar stroke. Meta-analysis of results from 27 studies showed that on average, infarct size and neurobehavioral 
outcome were improved by 34.2% (24.1–44.2) and 0.82 standardized mean difference (0.51–1.14), respectively. Four 
interventions improved both infarct size and neurobehavioral outcome but there were insufficient data for this finding 
to be considered robust. For infarct size, efficacy was lower in studies reporting blinding and higher in studies reporting 
randomization. For neurobehavior, efficacy was lower in randomized studies. For infarct size there was evidence of 
publication bias.
Conclusions—No intervention has yet been tested in sufficient range and depth to support translation to clinical trial. 
There is limited reporting of measures to reduce the risk of bias and evidence for a substantial publications bias.
(Stroke. 2014;45:563-570.)
Key Words: meta-analysis ◼ review, systematic ◼ stroke, lacunar
Systematic Review and Meta-Analysis of Interventions 
Tested in Animal Models of Lacunar Stroke
Hugo Pedder, BSc; Hanna M. Vesterinen, PhD; Malcolm R. Macleod, PhD, FRCP(Edin); 
Joanna M. Wardlaw, MD
Received August 7, 2013; final revision received October 16, 2013; accepted November 4, 2013.
From the Department of Clinical Neurosciences, Western General Hospital, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, 
Scotland, United Kingdom.
Guest Editor for this article was Christoph Kleinschnitz, MD.
The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.
113.003128/-/DC1.
Correspondence to Malcolm R. Macleod, PhD, FRCP(Edin), Department of Clinical Neurosciences, Western General Hospital, Centre for Clinical Brain 
Sciences, University of Edinburgh, Crewe Rd, Edinburgh, Scotland, United Kingdom. E-mail Malcolm.macleod@ed.ac.uk
© 2014 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.113.003128
Basic Sciences
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
(EVAL PDF Extractor SDK 8.0.0.2542-1055770970)
[Link]
http://www.camarades.info/index_files/protocols.htm
[Link]
http://www.camarades.info/index_files/protocols.htm
[Link]
http://stroke.ahajournals.org/
564 Stroke February 2014
have given useful insights to the impact of study design and 
quality13–16 within the limitations inherent in combining data 
from different studies. Here, we assess the evidence supporting
the efficacy of different treatments tested in animal models 
of lacunar stroke on behavioral and structural outcomes, with 
particular focus on the reporting and impact of measures to 
reduce bias and on the likelihood of publication bias.
Methods
The study protocol is available at www.camarades.info/index_files/
protocols.htm, and further details of the methodological approach are 
given in Vesterinen et al.17
Search Strategy
We searched Medline (from 1950), ISI Web of Science (from 1969), 
and EMBASE (from 1980) on March 6, 2012, with a strategy to identify
animal experiments modeling lacunar stroke (including but not 
limited to intervention studies) modified from a previously reported
search strategy18 and described in detail in the online-only Data 
Supplement. In addition, we searched (March 23, 2012) for publications
citing original studies identified in the previous systematic 
review of the animal modeling of lacunar stroke.18 There were no 
language restrictions.
Inclusion and Exclusion Criteria
We included experiments where animals had been exposed to a lesion 
modeling lacunar stroke (defined as those caused by occlusion or 
stenosis or other disease of perforating blood vessels and leading to 
presumed ischemic lesions in focal subcortical areas)18,19 and where 
outcome in a cohort of animals subject to an intervention was compared
with that in a control group. We included studies that quantified
structural (lesion size) or functional (behavioral) outcomes. We 
excluded studies where single lesions were >1 of 140th of total brain 
volume, where lesions were not induced by single-vessel mechanisms
(eg, traumatic brain injury), hemorrhages, and those involving
partial or complete occlusion of the middle cerebral or common 
carotid artery. We excluded transgenic studies and those modeling 
neonatal hypoxia/ischemia. We excluded studies where the intervention
was given with the expressed intention of worsening rather than 
improving outcome.
Data Extraction
We recorded the author, year of publication, intervention used and 
dose, type of animal (including species, strain, and sex), type of intervention
, time of administration and of outcome assessment, outcome
measure used, mean outcome, SD or SE, number of animals 
per group, presence of salt loading, method of stroke induction, anesthetic
used, study quality assessment parameters, and reporting of 
measures to avoid bias (see below).
We defined treatment comparisons as those which compared the 
outcome in control and treated animals. For studies using spontaneously
hypertensive stroke–prone rats (SHRSPs), we did not record 
time of administration or outcome assessment, as there was no clear 
time point at which stroke was induced. Where >1 intervention was 
given, we considered this combination to be a separate, unique intervention.
Where treatment was administered in multiple doses, we 
considered treatment to occur at the time of the first dose and the dose 
to be the sum of all doses administered in the first 24 hours. Where 
data from multiple brain slices were reported, we included only the 
infarct size from the slice with the largest corresponding infarct in 
control animals. Where neurobehavioral outcomes were reported for 
>1 time point, we included only the latest time of assessment as the 
most clinically relevant end point. Where data were presented graphically
, we contacted authors seeking further information, and if necessary
we measured values from graphs (Universal Desktop Ruler, 
version 2.9).
Quality Assessment
Risk of bias was assessed using 8 of 10 Collaborative Approach 
to Meta-Analysis and Review of Animal Data from Experimental 
Studies (CAMARADES) checklist items.13 We did not include statement
of control of temperature or avoidance of anesthetics with 
marked intrinsic properties as we considered these less relevant in 
models of lacunar stroke. We recorded whether the study was (1) 
published in a peer-reviewed journal, and whether it reported (2) 
randomized allocation to experimental group; (3) the blinding of the 
group allocation during the conduct of the experiment; (4) the blinded 
assessment of outcome; (5) the use of animals with relevant comorbidities
; (6) a statement of sample size calculation; (7) a statement 
of compliance with regulatory requirements; and (8) a statement on 
possible conflicts of interest.
Data Analysis
We anticipated substantial heterogeneity between studies so used 
DerSimmonian and Laird random-effects meta-analysis. For infarct 
size we assumed that unlesioned animals would have no infarct, and 
therefore we used a normalized mean difference approach and report 
percentage improvement in infarct volume. For behavioral outcomes 
it was not always possible to infer, for the test reported, how an unlesioned
animal would perform, so we used a standardized mean difference
(SMD) approach and report SMDs in units of SD. Where >1 
functional outcome was reported for the same cohort of animals at the 
same time point, we combined these in a fixed-effects meta-analysis 
to give a summary estimate of efficacy at that time point, and the last 
time point was used for meta-analysis. We used stratified analysis 
with partitioning of heterogeneity to test the extent to which 8 study 
characteristics explained differences in reported efficacy, with a critical
threshold of P<0.057 determined using Bonferroni correction to 
account for multiple comparisons. This approach tests whether studies
are drawn from the same population, but not whether the point 
estimates in strata are significantly different. Therefore, for randomization
and blinding, we calculated the impact of not reporting these 
measures as a relative change in efficacy compared with studies 
which did, along with a 95% confidence interval (CI).
SHRSPs were excluded from analyses comparing delay from 
stroke to drug administration and to outcome assessment as there 
was no clear time point at which stroke occurred in these studies. 
Continuous data are reported as mean±95% CI and discrete data are 
reported as median with interquartile range.
We assessed publication bias using funnel plot and Egger regression20,21 and used trim and fill (STATA, version 10) to estimate the 
number of missing publications and to calculate adjusted global efficacy.22 Because the process of pooling data from different behavioral
outcomes measured at the same time point would confound the 
analysis of publication bias, we used all data rather than pooled data, 
resulting in a different global estimate of efficacy in the publication 
bias analysis.
Results
Study Characteristics
Our electronic search identified 4379 publications of which 
4322 were excluded, leaving 57 for inclusion in the systematic 
review (see online-only Data Supplement).
Lacunar stroke was introduced by microthrombi injection
into the internal carotid artery in 16 of 57 studies (28%), 
microsphere injection into the internal carotid artery in 15 
(25%), and endothelin injection into deep gray matter in 12 
(21%). Salt loading to accelerate the occurrence of spontaneous
stroke in SHRSPs, and spontaneous strokes without salt 
loading in SHRSPs, was each used in 5 studies (9%). A total 
of 41 (72%) used rats, with others using rabbits or mice (see 
online-only Data Supplement). Only 47 studies reported using 
an anesthetic during stroke induction.
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
(PDF Extractor SDK TRIAL VERSION)
[Link]
http://stroke.ahajournals.org/
Pedder et al Interventions in Animal Models of Lacunar Stroke 565
The median number of study quality checklist items scored 
was 3 of 8 (interquartile range, 2–4). All studies had been 
published in peer-reviewed journals. Twenty-six of 57 (46%) 
studies reported randomized allocation to treatment group, 10 
(18%) reported blinding to group allocation during the experiment
, 26 (46%) reported blinded assessment of outcome, 12 
(21%) used animals with relevant comorbidities (hypertension
), 7 (12%) stated possible conflicts of interest, 5 (9%), all 
Figure 2. A significant impact of reporting randomizing was found on neurobehavioral calculated using standardized mean differences 
(SMDs; A) and infarct size calculated using normalized mean differences (B). A significant impact of reporting blinding was found on 
infarct size (B) but not on neurobehavioral score (A). Vertical error bars represent 95% confidence interval (CI). Horizontal gray bars represent
the 95% CI of the global estimate of efficacy. Bar widths represent the relative number of animals in each comparison. The relative 
change in reported efficacy for neurobehavioral scores and infarct size in nonrandomized and unblinded studies are shown in C.
Figure 1. Timber plots of the improvement in neurobehavioral scores for 18 interventions calculated using standardized mean differences 
(SMDs; A) and infarct size for 18 different interventions calculated using normalized mean differences (B). Horizontal error bars represent 
95% confidence interval (CI). Vertical gray bars represent the 95% CI of the global estimate of efficacy. Symbol sizes represent the relative
number of animals tested for each intervention. NDP-a-MSH indicates [Nle(4), D-Phe(7)]-<alpha>-Melanocyte-stimulating hormone; 
and PPP, (3-(3-hydroxyphenyl)-N-n-propylpiperidine). 
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
(BY PDF Extractor SDK TRIAL VERSION)
[Link]
http://stroke.ahajournals.org/
566 Stroke February 2014
from the same laboratory,23–27 reported a sample size calculation
, and 44 (77%) stated compliance with animal welfare 
regulatory requirements (see online-only Data Supplement).
Meta-Analysis
Data from 16 publications could not be included in the 
meta-analysis because key information such as variance or, 
in the case of lesion size, data for unlesioned animals were 
not reported or could not be inferred. Thirteen publications 
reported the quantity of microclots producing neurological 
dysfunction in 50% of animals. Although an entirely valid 
model of lacunar stroke, these do not provide data suitable for 
meta-analysis and so were excluded. Twenty-seven remaining 
publications described 67 experiments involving 1099 animals
reporting the efficacy of 22 drugs; of these, 37 experiments
using 736 animals reported changes in neurobehavior, 
and 30 experiments using 422 animals reported infarct size 
(see online-only Data Supplement).
Efficacy
Overall, neurobehavioral score was improved by 0.82 SMD 
(95% CI, 0.51–1.14; 37 comparisons; 736 animals) in experiments
testing 18 interventions, with substantial heterogeneity
between studies (χ2=170.3; I2=79%; df=36; P<0.0057). 
Stratification by intervention showed significant improvement
in outcome for 8 of 18 interventions (χ2=128.4; df=17; 
P<0.0057; Figure 1A).
Infarct size was improved by 34.3% (95% CI, 24.2%–
44.4%; 30 comparisons; 422 animals) in experiments testing 
18 interventions, and again there was substantial heterogeneity
(χ2=91.0; I2=68%; df=29; P<0.0057). Stratified analysis by 
intervention showed significant improvement in outcome for 
10 of 18 interventions (χ2=83.1; df=17; P<0.0057; Figure 1B).
Four interventions improved both neurobehavioral outcome
and infarct size: preclamol (1 publication, 68 animals, 
4 quality checklist items scored), fasudil (1 publication, 44 
animals, 2 quality checklist items scored), nicotiflorin (1 
publication, 48 animals, 4 quality checklist items scored), 
and hepatocyte growth factor (1 publications, 21 animals, 2 
quality checklist items scored). Other compounds improved 
either neurobehavior (DY9760e, atorvastatin, hydroxyfasudil, 
ozagrel) or infarct size (dihydralazine, neural progenitor cells, 
γ-hydroxybutyrate, cilostazol, modafinil, and minocycline) 
but not both, although for 4 of these drugs only neurobehavior
(atorvastatin, ozagrel) or infarct size (dihydralazine, cilostazol
) was reported.
Study Quality
For neurobehavioral score, stratifying studies by randomization
status, but not by blinding status, explained a significant 
proportion of the observed heterogeneity (Figure 2A). The 
impact of nonrandomization was a relative increase in reported 
efficacy of +282% (95% CI, +17% to +546%; Figure 2C). 
There was no apparent effect of blinding (relative reduction in 
efficacy of –8% [95% CI, –110% to +94%]) or of the use of 
animals with relevant comorbidities (Figure 2C).
For infarct size, stratifying studies by either randomization
or blinding status explained a significant proportion of 
the observed heterogeneity (Figure 2B). The impact of nonrandomization
was a relative reduction in efficacy of –25.5% 
(95% CI, –84.3% to +33.1), and of nonblinding a relative 
increase in reported efficacy of +28.4% (95% CI, –60% to 
+116%; Figure 2C). There was no apparent difference in 
animals with comorbidities. Overall, the number of study 
quality checklist items scored explained a significant proportion
of the observed heterogeneity for both neurobehavioral 
score (χ2=21.0; df=4; P<0.0057; Figure 3A) and infarct size 
(χ2=44.3; df=5; P<0.0057; Figure 3B), with highest quality 
studies giving the lowest estimates of efficacy.
Publication Bias
Funnel plotting showed obvious asymmetry for neurobehavioral
outcome (Figure 4A) but not infarct size (Figure 4B), 
whereas Egger regression suggested publication bias for both 
Figure 3. Efficacy falls as aggregate study quality score increases for neurobehavioral outcome calculated using standardized mean differences
(SMDs; A) and infarct size calculated using normalized mean differences (B). Vertical error bars represent 95% confidence interval
(CI). Horizontal gray bars represent the 95% CI of the global estimate of efficacy. Bar widths represent the relative number of animals 
in each comparison.
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
(DEMO PDF Extractor SDK 8.0.0.2542-1706811290)
[Link]
http://stroke.ahajournals.org/
Pedder et al Interventions in Animal Models of Lacunar Stroke 567
(Figure 4C and 4D). Using trim and fill analysis, we estimate 
20 unpublished neurobehavioral outcomes (Figure 4A) giving
an adjusted overall effect of 0.13 SMD (95% CI, –0.30 
to 0.55; compared with 1.04 SMD [95% CI, 0.67–1.40]). For 
infarct size, we estimate 2 unpublished studies (Figure 4B) 
with a small reduction in the global efficacy from 33.9% (95% 
CI, 24.4–43.3) to 33.0% (95% CI, 24.4–42.4).
Study Characteristics
For neurobehavioral score, interventions administered 
intraperitoneally were the most effective (1.62 SMD; 95% 
CI, 0.90–2.34) and those administered intrastriatally the 
least (–0.15 SMD; 95% CI, –0.66 to 0.37; χ2=31.3; df=6; 
P<0.0057; Figure 5A). Highest efficacy was reported in studies
using spontaneous stroke in SHRSPs (1.56 SMD; 95% CI, 
0.60–2.52) and lowest efficacy in those using microspheres 
(0.50 SMD; 95% CI, –0.02 to 1.02; χ2=23.3; df=4; P<0.0057; 
Figure 5B). Studies assessing outcome within 1 week after 
stroke reported highest efficacy (1.12 SMD; 95% CI, 0.58–
1.65). This was significantly lower for later times of assessment
—those assessing outcome >1 month after stroke did not 
report significant improvement (–0.06 SMD; 95% CI, –0.60 
to 0.48; χ2=18.7; df=4; P<0.0057; Figure 5C).We found no 
significant impact of the timing of treatment.
For infarct size, interventions administered >3 hours after 
stroke onset were substantially less effective (20.8%; 95% 
CI, 6.8–34.7) than those given within 3 hours (37.4%; 95% 
CI, 20.0–54.9) or before stroke onset (43.6%; 95% CI, 17.1–
70.1; χ2=22.1; df=3; P<0.0057; Figure 6A). Where outcome 
was measured 1 to 3 weeks after stroke, efficacy was significantly
lower than at other times (14.1%; 95% CI, –4.7 to 32.8), 
whereas the highest efficacy was found in studies assessing 
outcome in the first week (43.3%; 95% CI, 20.9–65.8; χ2=42.4; 
df=2; P<0.0057; Figure 6B). We found no significant impact of 
the route of administration or method of stroke induction.
Discussion
We report the meta-analysis of 22 interventions tested in 7 distinct
animal models of lacunar stroke. Fourteen interventions 
improved either infarct size or neurobehavioral outcomes, 
of which 10 already have Food and Drug Administration 
approval for other indications.28 However, the low prevalence 
of measures to reduce bias compromises the internal validity 
of the data and the likelihood of publication bias compromises 
Figure 4. Funnel plots for neurobehavioral (A) and infarct size (B) showing the distribution of published study outcomes (black circles) 
and unpublished outcomes (grey circles) estimated by Trim and Fill analysis. Vertical gray lines represent the global estimate of efficacy. 
Egger regression plots for neurobehavioral (C) and infarct size (D) showing regression lines with 95% confidence interval. by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
(PDF Extractor SDK TRIAL VERSION)
[Link]
http://stroke.ahajournals.org/
568 Stroke February 2014
their external validity; even for apparently promising interventions
these concerns suggest the need for further high quality 
in vivo data in relevant models before embarking on clinical 
trials, particularly of novel agents.
Potential Weaknesses
This study is observational, analyzing previously collected 
data, and our findings are only hypothesis-generating; it may 
be that observed differences are because of some other factor
that cosegregates with the variable of interest, and the 
data set is too small to allow multivariate analysis. We were 
unable to extract required data from 11 publications. Because 
low-quality studies overstate efficacy, and we included all 
studies, we will have overestimated treatment effects. Many 
of the experimental models reflect mechanisms that are not 
relevant to most lacunar stroke in humans. Some data from 
SHRSPs, the most relevant current model, could not be 
included through lack of time about stroke onset.
Efficacy
Four interventions improved both neurobehavioral outcome 
and infarct size. Of the four, only fasudil has been tested clinically
, with promising initial results.29 Several other available 
agents improved the one outcome on which they were tested. 
In focal ischemia, stable estimates of efficacy emerge with 
data from ≈1000 animals,30 and we think that, even for these 
promising treatments, more and better evidence of efficacy in 
animals is required to help plan clinical trials.
Risk of Bias
The prevalence of reporting of measures to avoid bias, while 
modest, compares well with systematic reviews in stroke15,31,32
Figure 5. Significant impact of route of drug delivery (A), method of stroke induction (B), and time of outcome assessment (C) on neurobehavioral
score calculated using standardized mean differences (SMDs). Vertical error bars represent 95% confidence interval (CI) and 
horizontal gray bars represent the 95% CI of the global estimate of efficacy. Bar widths represent the relative number of animals in each 
comparison.
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
(EVALUATION PDF Extractor SDK 8.0.0.2542.749011608)
[Link]
http://stroke.ahajournals.org/
Pedder et al Interventions in Animal Models of Lacunar Stroke 569
and other neurological conditions.14,16 Studies reporting fewest
measures to avoid bias gave highest measures of treatment
effect. The overstatement of efficacy in nonrandomized 
studies reporting neurobehavioral outcome is consistent with 
previous findings.14–16,31,32 Although stratification of infarct 
volume by randomization or blinding status explained a significant
proportion of the observed heterogeneity, the strata 
were different in other respects; for instance, the median time 
to treatment was substantially shorter in randomized studies. 
With the exception of randomization status and neurobehavioral
score, the 95% CIs for the difference in efficacy in studies
at risk of bias include zero. The difference in impact of 
nonrandomization between studies reporting neurobehavioral 
outcome and those reporting infarct size may be because of 
the confounding effect of other variables, or to a true difference
perhaps because of baseline differences in neurobehavioral
performance biasing group allocation in nonrandomized 
studies. We think the evidence for small study effects, particularly
for neurobehavioral outcomes, reflects publication bias; 
this provides further support for the development of systems 
to address this issue.
Diverse lesions are used to model lacunar stroke, and it 
is not clear whether there is 1 best model, or whether different
models are suited to different research questions.18
Thromboembolism is an unusual cause of human lacunar 
stroke4 but more than half of the included studies used an 
embolic model. This substantially limits the relevance of the 
data reported here and highlights the need for use of more 
relevant existing models and the development of better models 
of lacunar stroke. Spontaneous strokes in the SHRSPs may 
be more similar to human lacunar stroke,33 so focus on this 
model may be relevant. Future trials’ design should account 
for assessing when stroke occurs in spontaneous lacunar models.
Brain damage in patients with lacunar stroke is generally 
not confined to the tissue affected by the stroke but is much 
more diverse because of the diffuse nature of SVD. Therefore, 
a diffuse model, such as the SHRSPs, seems more relevant for 
drug testing as it models both recovery from the index stroke 
and these other cerebral effects of SVD.
Even a small improvement in outcome, if in an appropriate
model, at an appropriate time and in an experiment at low 
risk of bias, might provide substantial evidence on which to 
embark on clinical trial. However, to have adequate power 
such studies would have to be substantially larger those identified
here, and it may be that this can only be achieved in 
multicenter animal studies.34,35
Evidence-Based Clinical Trial Design
Lacunar stroke is part of the spectrum of SVD. Patients who 
present with an acute lacunar stroke syndrome might start 
treatment to prevent recurrent lacunar stroke immediately. 
However, other SVD features typically accumulate silently, 
and patients might not present for treatment until they develop 
cognitive or physical decline, at which stage efficacy may 
have declined. Treatments preventing further lacunar strokes 
would be useful, yet only 4 studies tested treatments administered
before stroke induction. An ideal treatment would have 
long-term efficacy preventing both the recurrence of clinically 
apparent acute lacunar stroke syndromes and the build up of 
silent features of SVD. It is therefore reassuring that over time 
the effect on neurobehavioral outcome did not seem to decline, 
and if anything the impact on structural outcome increased.
Conclusions
Our findings provide some guidance for future laboratory and 
clinical research. First, it is unclear which is the most appropriate
animal model of lacunar stroke in which to test interventions
; the most relevant current models raise trial design 
questions concerning how to detect and time new strokes. 
Second, improvements in internal (study quality) and external 
(publication bias) validity might provide a firmer foundation 
for the translation to clinical trials, and more robust exploration
of the limits to efficacy in such studies could inform the 
inclusion and exclusion criteria for such trials.
Acknowledgments
We thank Kieren Egan and Dr Emily Sena for their support and advice
during this study.
Figure 6. Significant impact of time of administration (A) and time of assessment (B) on infarct size calculated using normalized mean differences.
Vertical error bars represent 95% confidence interval (CI). Horizontal gray bars represent the 95% CI of the global estimate of 
efficacy. Bar widths represent the relative number of animals in each comparison.
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
( 8.0.0.2542.1168167645 PDF Extractor SDK EVALUATION)
[Link]
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
[Link]
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
[Link]
http://stroke.ahajournals.org/
570 Stroke February 2014
Sources of Funding
Dr Macleod is supported by the UK Medical Research Council Trials 
Methodology Hub, Dr Vesterinen holds a University of Edinburgh 
Centre for Clinical Brain Sciences PhD studentship; Dr Vesterinen 
acknowledges the support of the National Health Service Lothian 
Research and Development office. Dr Wardlaw is supported by the 
Scottish Funding Council through the Scottish Imaging Network—A 
Platform for Scientific Excellence initiative.
Disclosures
None.
References
1. Bamford JM, Warlow CP. Evolution and testing of the lacunar hypothesis. Stroke. 1988;19:1074–1082.
2. Millikan C, Futrell N. The fallacy of the lacune hypothesis. Stroke. 
1990;21:1251–1257.
3. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral
small vessel disease: insights from neuroimaging. Lancet Neurol. 
2013;12:483–497.
4. Del Bene A, Makin SDJ, Doubal FN, Inzitari D, Wardlaw JM. Variation 
in risk factors for recent small subcortical infarcts with infarct size, 
shape, and location. Stroke. 2013;44:3000–3006.
5. Fisher CM. Lacunar infarcts—a review. Cerebrovasc Dis. 
1991;1:311–320.
6. Knottnerus IL, Ten Cate H, Lodder J, Kessels F, van Oostenbrugge 
RJ. Endothelial dysfunction in lacunar stroke: a systematic review. 
Cerebrovasc Dis. 2009;27:519–526.
7. Giwa MO, Williams J, Elderfield K, Jiwa NS, Bridges LR, Kalaria RN, 
et al. Neuropathologic evidence of endothelial changes in cerebral small 
vessel disease. Neurology. 2012;78:167–174.
8. Sacco S, Marini C, Totaro R, Russo T, Cerone D, Carolei A. A 
population-based study of the incidence and prognosis of lacunar stroke. 
Neurology. 2006;66:1335–1338.
9. Norrving B. Long-term prognosis after lacunar infarction. Lancet 
Neurol. 2003;2:238–245.
10. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. Relation 
between age-related decline in intelligence and cerebral white-matter 
hyperintensities in healthy octogenarians: a longitudinal study. Lancet. 
2000;356:628–634.
11. Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten EC, van der 
Flier WM, et al; LADIS Study Group. Incident lacunes influence cognitive
decline: the LADIS study. Neurology. 2011;76:1872–1878.
12. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins 
V, et al. Can animal models of disease reliably inform human studies? 
PLoS Med. 2010;7:e1000245.
13. Sena E, van der Worp HB, Howells D, Macleod M. How can we improve 
the pre-clinical development of drugs for stroke? Trends Neurosci. 
2007;30:433–439.
14. Vesterinen HM, Sena ES, ffrench-Constant C, Williams A, Chandran S, 
Macleod MR. Improving the translational hit of experimental treatments 
in multiple sclerosis. Mult Scler. 2010;16:1044–1055.
15. Frantzias J, Sena ES, Macleod MR, Al-Shahi Salman R. Treatment of 
intracerebral hemorrhage in animal models: meta-analysis. Ann Neurol.
2011;69:389–399.
16. Rooke ED, Vesterinen HM, Sena ES, Egan KJ, Macleod MR. Dopamine 
agonists in animal models of Parkinson’s disease: a systematic review 
and meta-analysis. Parkinsonism Relat Disord. 2011;17:313–320.
17. Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, 
et al. Meta-analysis of data from animal studies: a practical guide.  
J Neurosci Methods. 2014;221:92–102.
18. Bailey EL, McCulloch J, Sudlow C, Wardlaw JM. Potential animal models
of lacunar stroke: a systematic review. Stroke. 2009;40:e451–e458.
19. Hainsworth AH, Brittain JF, Khatun H. Pre-clinical models of human 
cerebral small vessel disease: utility for clinical application. J Neurol Sci. 
2012;322:237–240.
20. Light RJ, Pillemer DB. Summing Up: The Science of Reviewing 
Research. Cambridge, MA: Harvard University Press; 1984.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis 
detected by a simple, graphical test. BMJ. 1997;315:629–634.
22. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of 
testing and adjusting for publication bias in meta-analysis. Biometrics. 
2000;56:455–463.
23. Lapchak PA, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 
12/15-lipoxygenase inhibitor improves clinical rating scores following 
multiple infarct embolic strokes. Neuroscience. 2007;150:585–591.
24. Lapchak PA, Zivin JA. The lipophilic multifunctional antioxidant edaravone
(radicut) improves behavior following embolic strokes in rabbits
: a combination therapy study with tissue plasminogen activator. 
Exp Neurol. 2009;215:95–100.
25. Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel 
neurotrophic compound reduces behavioral deficits in rabbit ischemic 
stroke. J Neurochem. 2011;116:122–131.
26. Lapchak PA. Efficacy and safety profile of the carotenoid trans sodium 
crocetinate administered to rabbits following multiple infarct ischemic 
strokes: a combination therapy study with tissue plasminogen activator. 
Brain Res. 2010;1309:136–145.
27. Lapchak PA, Han MK. Simvastatin improves clinical scores in a rabbit 
multiple infarct ischemic stroke model: synergism with a ROCK inhibitor
but not the thrombolytic tissue plasminogen activator. Brain Res. 
2010;1344:217–225.
28. FDA Approved Drug Products. U.S. Department of Health and Human 
Sciences Web site. http://www.accessdata.fda.gov/scripts/cder/drugsatfda
/. Accessed May 01, 2012.
29. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E; Fasudil Ischemic 
Stroke Study Group. Effects of fasudil in acute ischemic stroke: results 
of a prospective placebo-controlled double-blind trial. J Neurol Sci. 
2005;238:31–39.
30. Sena ES, Briscoe CL, Howells DW, Donnan GA, Sandercock PA, 
Macleod MR. Factors affecting the apparent efficacy and safety of tissue
plasminogen activator in thrombotic occlusion models of stroke: 
systematic review and meta-analysis. J Cereb Blood Flow Metab. 
2010;30:1905–1913.
31. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, 
Donnan GA. Evidence for the efficacy of NXY-059 in experimental
focal cerebral ischaemia is confounded by study quality. Stroke. 
2008;39:2824–2829.
32. Jerndal M, Forsberg K, Sena ES, Macleod MR, O’Collins VE, Linden T, 
et al. A systematic review and meta-analysis of erythropoietin in experimental
stroke. J Cereb Blood Flow Metab. 2010;30:961–968.
33. Bailey EL, Smith C, Sudlow CL, Wardlaw JM. Is the spontaneously 
hypertensive stroke prone rat a pertinent model of sub cortical ischemic 
stroke? A systematic review. Int J Stroke. 2011;6:434–444.
34. Bath PM, Macleod MR, Green AR. Emulating multicentre clinical stroke 
trials: a new paradigm for studying novel interventions in experimental 
models of stroke. Int J Stroke. 2009;4:471–479.
35. Dirnagl U, Fisher M. International, multicenter randomized preclinical 
trials in translational stroke research: it’s time to act. J Cereb Blood Flow 
Metab. 2012;32:933–935.
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
(TRIAL VER. PDF Extractor SDK 8.0.0.2542.90880355)
[Link]
http://stroke.ahajournals.org/content/45/2/563
[Link]
http://stroke.ahajournals.org/content/suppl/2014/01/02/STROKEAHA.113.003128.DC1.html
[Link]
http://stroke.ahajournals.org/content/suppl/2016/04/03/STROKEAHA.113.003128.DC2.html
[Link]
http://www.ahajournals.org/site/rights/
[Link]
http://www.lww.com/reprints
[Link]
http://stroke.ahajournals.org//subscriptions/
[Link]
http://stroke.ahajournals.org/
Hugo Pedder, Hanna M. Vesterinen, Malcolm R. Macleod and Joanna M. Wardlaw
Lacunar Stroke
Systematic Review and Meta-Analysis of Interventions Tested in Animal Models of
Print ISSN: 0039-2499. Online ISSN: 1524-4628 
Copyright © 2014 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Stroke 
doi: 10.1161/STROKEAHA.113.003128
2014;45:563-570; originally published online January 2, 2014; Stroke. 
http://stroke.ahajournals.org/content/45/2/563
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
http://stroke.ahajournals.org/content/suppl/2016/04/03/STROKEAHA.113.003128.DC2.html
http://stroke.ahajournals.org/content/suppl/2014/01/02/STROKEAHA.113.003128.DC1.html
Data Supplement (unedited) at:
http://stroke.ahajournals.org//subscriptions/
is online at: Stroke  Information about subscribing to Subscriptions:
http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
document. Permissions and Rights Question and Answer process is available in the
Request Permissions in the middle column of the Web page under Services. Further information about this
Once the online version of the published article for which permission is being requested is located, click 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Stroke in
 Requests for permissions to reproduce figures, tables, or portions of articles originally published Permissions:
 by guest on January 10, 2017 http://stroke.ahajournals.org/ Downloaded from 
( 8.0.0.2542.861408283 PDF Extractor SDK EVAL VERSION)
ONLINE SUPPLEMENT 
A systematic review and meta-analysis of interventions tested in animal models of lacunar 
stroke 
Hugo Pedder, Hanna M. Vesterinen, Malcolm R. Macleod*, Joanna M. Wardlaw 
Centre for Clinical Brain Sciences, University of Edinburgh, Scotland, UK 
* correspondence to  Prof. Malcolm Macleod 
Malcolm.macleod@ed.ac.uk
Department of Clinical Neurosciences 
University of Edinburgh 
Western General Hospital 
Crewe Road 
Edinburgh 
Scotland 
UK 
( 8.0.0.2542.861408283 PDF Extractor SDK EVAL VERSION)
Supplement I: Search strategy
Search strategy used for EMBASE. 
1.  exp Models, Biological/ or exp Disease Models, Animal/ or exp Models, Animal/  
2.   Animals/  
3.   exp mammals/ or exp primates/ or exp mice/ or exp rats/  
4.   1 or 2 or 3  
5.  exp cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp 
brain ischemia/ or exp cerebrovascular accident/ or exp brain infarction/ or exp hypoxia 
ischemia, brain/  
6.  brain edema/ or cerebrovascular accident/ or exp dementia, vascular/ or exp intracranial 
arterial diseases/ or exp vasospasm, intracranial/ 
7.   5 or 6  
8.   (Stroke$ or cerebrovasc$ or cerebral vasc$ or cerebral$).tw  
9.   4 and 7 and 8  
10.  limit 9 to animals  
11.  (((micro or small or perforat$) adj3 vessel) or arteriole).tw  
12.  (lacunar stroke or lacunar infarct).tw  
13.  ((small or micro) adj5 (stroke$ or occlusion$ or disease$)).tw  
14.  ((lacun$ or small or subcortical or deep or silent) adj5 (infarct$ or lesion$ or stroke$)).tw  
15.  11 or 12 or 13 or 14  
16.  10 and 15  
17.  (heart or bone or eye or lung or kidney or liver or renal or intestine$ or spinal or 
pulmonary or hepatic or global).mp  
18.  16 not 17  
19.  (AD or PD or Alzheimer$ or Parkinson$ or epilepsy or MS or Multiple Sclerosis).tw  
20.  18 not 19  
(WITH PDF Extractor SDK TRIAL VERSION)
Search strategy used for Medline. 
1.  Biological Models or Animal Disease Models or Animal Models 
2.   Animals 
3.   mammals or primates or mice or rats 
4.   1 or 2 or 3 
5.   cerebrovascular disorders or basal ganglia cerebrovascular disease or brain ischemia 
or cerebrovascular accident or brain infarction or brain hypoxia ischemia 
6.   brain edema or cerebrovascular accident or vascular dementia or intracranial arterial 
diseases or intracranial vasospasm 
7.   5 or 6 
8.   (Stroke* [TW] or cerebrovasc* [TW] or cerebral vasc* [TW] or cerebral* [TW]) 
9.   4 and 7 and 8 
10.  limit 9 to animals 
11.  micro vessel [tw] OR small vessel [tw] OR perforat* vessel [tw] OR arteriole [tw] 
12.  lacunar stroke [tw] OR lacunar infarct [tw] 
13.  small stroke* [tw] or small occlusion* [tw] or small disease* [tw] or micro stroke* [tw] or 
micro occlusion* [tw] or micro disease* [tw] 
14.  lacun* infarct* [tw] or lacun* lesion* [tw] or lacun* stroke* [tw] or small infarct* [tw] or 
small lesion* [tw] or small stroke* [tw] or subcortical infarct* [tw] or subcortical lesion* 
[tw] or subcortical stroke* [tw] or deep infarct* [tw] or deep lesion* [tw] or deep stroke* 
[tw] or silent infarct* [tw] or silent lesion* [tw] or silent stroke* [tw] 
15.  11 or 12 or 13 or 14 
16.  10 and 15 
17.  heart [tiab] or bone [tiab] or eye [tiab] or lung [tiab] or kidney [tiab] or liver [tiab] or renal 
[tiab] or intestine* [tiab] or spinal [tiab] or pulmonary [tiab] or hepatic [tiab] or global [tiab] 
18.  16 not 17 
19.  AD [tw] or PD [tw] or Alzheimer* [tw] or Parkinson* [tw] or epilepsy [tw] or MS [tw] or 
Multiple Sclerosis [tw] 
20.  18 not 19 
(8.0.0.2542,1280564320 PDF Extractor SDK TRIAL)
Search strategy used for ISI Web of Science. 
1.   Biological Models OR Animal Disease Models OR Animal Models 
2.   Animals 
3.   mammals OR primates OR mice OR rats 
4.   1 OR 2 OR 3 
5.   cerebrovascular disorders OR basal ganglia cerebrovascular disease OR brain 
ischemia OR cerebrovascular accident OR brain infarction OR brain hypoxia ischemia 
6.   brain edema OR cerebrovascular accident OR vascular dementia OR intracranial 
arterial diseases OR intracranial vasospasm 
7.   5 OR 6 
8.   Stroke* OR cerebrovasc* OR cerebral vasc* OR cerebral* 
9.   4 AND 7 AND 8 
10.  (((micro OR small OR perforat*) NEAR/3 vessel) OR arteriole) 
11.  lacunar stroke OR lacunar infarct 
12.  ((small OR micro) NEAR/5 (stroke* OR occlusion* OR disease*)) 
13.  ((lacun* OR small OR subcortical OR deep OR silent) NEAR/5 (infarct* OR lesion* OR 
stroke*)) 
14.  11 OR 12 OR 13 OR 14 
15.  10 AND 15 
16.  (heart OR bone OR eye OR lung OR kidney OR liver OR renal OR intestine* OR spinal 
OR pulmonary OR hepatic OR global) 
17.  16 not 17 
18.  (AD OR PD OR Alzheimer* OR Parkinson* OR epilepsy OR MS OR Multiple Sclerosis) 
19.  18 not 19 
( 8.0.0.2542.929192429 PDF Extractor SDK EVALUATION)
Supplement II: Quorum diagram showing summary of study selection procedure 
( 8.0.0.2542.929192429 PDF Extractor SDK EVALUATION)
Supplement III: Study characteristics report 
Author  Year  Intervention  Species 
Stroke 
Model 
No. of 
Animals 
Time of 
Admin 
(mins) 
Anaesthetic  Route of Delivery 
Outcome 
Type(s) 
Ando, T  2005 
Nefiracetam  Rat  Microspheres  8  900 
Sodium 
pentobarbital 
Oral  Infarct size 
Nefiracetam  Rat  Microspheres  12  900 
Sodium 
pentobarbital 
Oral  Neurobehavioural score 
Date, I  2004 
Hepatocyte growth 
factor 
Rat  Microspheres  15  10 
Sodium 
pentobarbital 
Intracerebroventricular  Infarct size 
Hepatocyte growth 
factor 
Rat  Microspheres  21  10 
Sodium 
pentobarbital 
Intracerebroventricular  Neurobehavioural score 
Dong, Y  2011 
Valsartan  Rat  High salt  11  0  None  Oral  Infarct size
Amlodipine  Rat  High salt  11  0  None  Oral  Infarct size 
Fujita, Y  2008  Cilostazol  Rat 
Spontaneous 
in SHRSP 
18  N/A  None  Oral  Infarct size 
Fuxe, K  1992  Dihydralazine  Rat  Endothelin  6  0  Halothane  Intrastriatal  Infarct size 
Guiliani, D  2007 
Preclamol  Rat  Endothelin  12  180  Chloral hydrate  Intraperitoneal  Infarct size 
Preclamol  Rat  Endothelin  12  540  Chloral hydrate  Intraperitoneal  Infarct size 
Preclamol  Rat  Endothelin  22  180  Chloral hydrate  Intraperitoneal  Neurobehavioural score 
Preclamol  Rat  Endothelin  22  540  Chloral hydrate  Intraperitoneal  Neurobehavioural score 
Han, F  2006  DY-9760e  Rat  Microspheres  12  30  Halothane  Intraperitoneal  Neurobehavioural score 
Hayashi, A  2004  Atorvastatin  Rat 
Spontaneous 
in SHRSP 
26  0  None  Oral  Neurobehavioural score 
(DEMO VERSION PDF Extractor SDK 8.0.0.2542.1699720357)
Author  Year  Intervention  Species 
Stroke 
Model 
No. of 
Animals 
Time of 
Admin 
(mins) 
Anaesthetic  Route of Delivery 
Outcome 
Type(s) 
Hewlett, K  2006 
Minocycline  Rat  Endothelin  42  120  Isoflurane  Intrastriatal  Infarct size 
Minocycline  Rat  Endothelin  30  120  Isoflurane  Intrastriatal  Neurobehavioural score 
Hua, R  2006  Minocycline  Rat  Surgery  12  60  Ketamine xylazine  Intraperitoneal  Infarct size 
Huang, J  2007 
Nicotiflorin  Rat 
Microthrombi 
injection 
24  -7200  Chloral hydrate  Oral  Infarct size 
Nicotiflorin  Rat 
Microthrombi 
injection 
120  -7200  Chloral hydrate  Oral  Neurobehavioural score 
Imamura, T  2003 
Norphenazone  Rat 
Sodium 
laurate 
thrombosis 
32  5 
Sodium 
pentobarbital 
Intravenous  Neurobehavioural score 
Ozagrel  Rat 
Sodium 
laurate 
thrombosis 
32  5 
Sodium 
pentobarbital 
Intravenous  Neurobehavioural score 
Lecrux, C  2008 
Magnesium sulphate  Rat  Endothelin  30  -30  Halothane Intraarterial  Infarct size 
Magnesium sulphate  Rat  Endothelin  30  -30  Halothane Intraarterial  Neurobehavioural score 
Miyake, K  1994 
Naftidrofuryl  Rat  Microspheres  14  900 
Sodium 
pentobarbital 
Intraperitoneal  Infarct size 
Naftidrofuryl  Rat  Microspheres  106  900 
Sodium 
pentobarbital 
Intraperitoneal  Neurobehavioural score 
Mochizuki, N  2011 
Neural progenitor 
transplant 
Rat  Microspheres  12  10080  Unknown  Intrahippocampus Infarct size 
Neural progenitor 
transplant 
Rat  Microspheres  12  10080  Unknown  Intrahippocampus Neurobehavioural score 
Neural progenitor 
transplant 
Rat  Microspheres  12  10080  Unknown  Intravenous  Infarct size 
Neural progenitor 
transplant 
Rat  Microspheres  12  10080  Unknown  Intravenous  Neurobehavioural score 
(BY PDF Extractor SDK TRIAL VERSION)
Author  Year  Intervention  Species 
Stroke 
Model 
No. of 
Animals 
Time of 
Admin 
(mins) 
Anaesthetic  Route of Delivery 
Outcome 
Type(s) 
Mochizuki, N  2008 
Neural progenitor 
transplant 
Rat  Microspheres  34  Unknown 
Sodium 
pentobarbital 
Intracerebroventricular  Infarct size 
Neural progenitor 
transplant 
Rat  Microspheres  14  Unknown 
Sodium 
pentobarbital 
Intracerebroventricular  Neurobehavioural score 
Nagakura, A  2002  Rolipram  Rat  Microspheres  32  360 
Sodium 
pentobarbital 
Intraperitoneal  Neurobehavioural score 
Ottani, A  2009  NDP-α-MSH  Rat  Endothelin  8  180  Chloral hydrate  Intrapenitoneal  Infarct size 
Ottani, A  2003 
Gammahydroxybutyrate
Rat  Endothelin  12  120  Ketamine xylazine  Intraperitoneal  Infarct size 
Gammahydroxybutyrate
Rat  Endothelin  36  120  Ketamine xylazine  Intraperitoneal  Neurobehavioural score 
Satoh, S  2010 
Hydroxy fasudil  Rat 
Sodium 
laurate 
thrombosis 
30  5 
Sodium 
pentobarbital 
Intraperitoneal  Infarct size 
Hydroxy fasudil  Rat 
Sodium 
laurate 
thrombosis 
30  5 
Sodium 
pentobarbital 
Intraperitoneal  Neurobehavioural score 
Shirakura, T  2005  DY-9760e  Rat  Microspheres  16  -30 Halothane  Intraperitoneal  Infarct size 
Takeo, S  2003 
Nefiracetam  Rat  Microspheres  20  900 
Sodium 
pentobarbital 
Oral  Infarct size 
Nefiracetam  Rat  Microspheres  20  900 
Sodium 
pentobarbital 
Oral  Neurobehavioural score 
Takeo, S  2003  Nefiracetam  Rat  Microspheres  14  900 
Sodium 
pentobarbital 
Oral  Neurobehavioural score 
Takeo, S  2003  Nefiracetam  Rat  Microspheres  14  900 
Sodium 
pentobarbital 
Oral  Neurobehavioural score 
Toshima, Y  2000 
Fasudil  Rat 
Sodium 
laurate 
thrombosis 
45  5 
Sodium 
pentobarbital 
Intraperitoneal  Infarct size 
Fasudil  Rat 
Sodium 
laurate 
thrombosis 
45  5 
Sodium 
pentobarbital 
Intraperitoneal  Neurobehavioural score 
(EVAL PDF Extractor SDK 8.0.0.2542-741920675)
Author  Year  Intervention  Species 
Stroke 
Model 
No. of 
Animals 
Time of 
Admin 
(mins) 
Anaesthetic  Route of Delivery 
Outcome 
Type(s) 
Ueki, A  1993 
Modafinil  Rat  Endothelin  19  -30  Halothane  Intraperitoneal  Infarct size 
Modafinil  Rat  Endothelin  20  -30  Halothane  Intraperitoneal  Neurobehavioural score 
Whitehead, S  2005  Trifusal  Rat  Endothelin  20  10080 
Sodium 
pentobarbital 
Oral  Neurobehavoural score 
(EVAL PDF Extractor SDK 8.0.0.2542-741920675)
Supplement IV: Study quality score report
1. Publication in a peer reviewed journal  
2. Random allocation to group  
3. Blinded induction of ischaemia  
4. Blinded assessment of outcome  
5. Use of comorbid animals  
6. Sample size calculation  
7. Compliance with animal welfare regulations  
8. Statement of a potential conflict of interest  
Author Year (1) (2) (3) (4) (5) (6) (7) (8) Quality Score
Amenta,f 1996 + + + 3
Ando,T 2005 + + + + 4
Antonucci,F 2010 + + + 3
Date,I 2004 + + 2
Dong,Y 2011 + + + + + 5
Fujita,Y 2008 + + 2
Fuxe,K 1992 + 1
Giuliani,D 2007 + + + + 4
Han,F 2006 + + 2
Hayashi,A 2004 + + + + 4
Hewlett,K 2006 + + + + 4
Horie,N 2008 + + 2
(8.0.0.2542,1161076712 PDF Extractor SDK TRIAL)
Author Year (1) (2) (3) (4) (5) (6) (7) (8) Quality Score
Hua,R 2006 + + 2
Huang,J 2007 + + + + 4
Imamura,T 2003 + + + 3
Ishizuka,T 2007 + + + + + + 6
Lapchak,P 2002 + + 2
Lapchak,P 2002 + + + 3
Lapchak,P 2003 + + + 3
Lapchak,P 2004 + + + + 4
Lapchak,P 2004 + + + 3
Lapchak,P 2004 + + + + + 5
Lapchak,P 2004 + + 2
Lapchak,P 2007 + + + + + 5
Lapchak,P 2007 + + + + + + 6
Lapchak,P 2009 + + + + 4
Lapchak,P 2010 + + + + + + 6
Lapchak,P 2010 + + + + + 5
Lapchak,P 2010 + + + + + 5
Lapchak,P 2011 + + + + + + 6
Lecrux,C 2008 + + + + + + + 7
Miyake,K 1994 + + 2
(PDF Extractor SDK TRIAL VERSION)
Author Year (1) (2) (3) (4) (5) (6) (7) (8) Quality Score
Mochizuki,N 2008 + + + 3
Mochizuki,N 2011 + + + 3
Nagakura,A 2002 + + + 3
Nakamura,T 2007 + + + + + + 6
Oshikawa,S 2004 + + 2
Ottani,A 2003 + + + 3
Ottani,A 2009 + + + 3
Park,L 2001 + + 2
Roos,M 1999 + + 2
Satoh,S 2010 + + 2
Shinyama,H 1998 + + 2
Shirakura,T 2005 + + + 3
Takagi,N 1996 + + 2
Takeo,S 1997 + + + 3
Takeo,S 2003 + + + 3
Takeo,S 2003 + + + 3
Takeo,S 2003 + + + 3
Tanaka,N 2007 + + + 3
Toshima,Y 2000 + + 2
Ueki,A 1993 + 1
( 8.0.0.2542.1041589104 PDF Extractor SDK EVAL VERSION)
Author Year (1) (2) (3) (4) (5) (6) (7) (8) Quality Score
Ueno,H 2000 + + 2
Wengenmayer,C 2011 + + + + 4
Whitehead,S 2005 + + 2
Whitehead,S 2010 + + + 3
Zivin,J 1985 + + + 3
(PDF Extractor SDK TRIAL VERSION)
Supplement V: Outcome measures 
Author  Year  Outcome Type  Outcome Measure 1  Outcome Measure 2 
Outcome 
Measure 3 
Outcome 
Measure 4 
Outcome 
Measure 5 
Ando, T  2005 
Infarct size 
Infarct area (% of 
hippocampus) 
Neurobehavioural score 
Neurological deficit score (10 
point scale) 
Morris water maze latency 
(sec) 
Date, I  2004 
Infarct size  Viable area (% of hemisphere)         
Neurobehavioural score 
Morris water maze latency 
(sec) 
Dong, Y  2011  Infarct size 
WML grade in corpus 
callossum (4 point scale) 
Fujita, Y  2008  Infarct size 
WML grade in corpus 
callossum (4 point scale) 
Fuxe, K  1992  Infarct size  Infarct area (% of striatum)         
Guiliani, D  2007 
Infarct size  Infarct size (mm3)         
Neurobehavioural score 
Morris water maze memory 
assay latency (sec) 
Morris water maze learning 
assay latency (sec) 
Han, F  2006  Neurobehavioural score 
Neurological deficit score (5 
point scale) 
Hayashi, A  2004  Neurobehavioural score 
Neurological deficit score (15 
point scale) 
Hewlett, K  2006 
Infarct size  Infarct size (mm3)  White matter index rostral  
White matter index 
caudal 
White matter index 
medial 
Neurobehavioural score 
Cylinder forelimb asymmetry 
task (% dependence on 
ipsilateral forelimb) 
Montoya staircase reaching 
tast (% of presurgery 
performance) 
Hua, R  2006  Infarct size  Infarct size (mm3)         
(TRIAL PDF Extractor SDK 8.0.0.2542-83789422)
Author  Year  Outcome Type  Outcome Measure 1  Outcome Measure 2 
Outcome 
Measure 3 
Outcome 
Measure 4 
Outcome 
Measure 5 
Huang, J  2007 
Infarct size  % of total stained volume         
Neurobehavioural score 
Neurological deficit score (10 
point scale) 
8-arm radial maze number 
wrong choices 
8-arm radial maze 
number correct 
choices 
Imamura, T  2003  Neurobehavioural score 
Posture test score (3 point 
scale) 
Lecrux, C  2008 
Infarct size  Infarct size (mm3)         
Neurobehavioural score 
Cylinder assessment of 
forelimb asymmetry (variation 
of total placements from 
baseline %) 
Walking ladder test right 
forelimb mean score (7 point 
scale) 
Walking ladder test 
left forelimb mean 
score (7 point 
scale) 
Walking ladder test 
right hindlimb mean 
score (7 point 
scale) 
Walking ladder test 
left hindimb mean 
score (7 point 
scale) 
Miyake, K  1994 
Infarct size 
Sum of TTC stained area in 3 
slices (mm2) 
Neurobehavioural score 
Neurological deficit score (10 
point scale) 
Mochizuki, 
N 
2011 
Infarct size 
Viable area (% of contralateral 
hemisphere) 
Neurobehavioural score 
Neurological deficit score (10 
point scale) 
Morris water maze retention 
latency (sec) 
Modified 
neurological 
severity score (19 
point scale) 
Mochizuki, N  2008 
Infarct size 
Viable area (% of contralateral 
hippocampus) 
Neurobehavioural score 
Neurological deficit score (10 
point scale) 
Nagakura, A  2002  Neurobehavioural score 
Morris water maze latency 
(sec) 
Morris water maze distance 
swam (cm) 
Ottani, A  2009  Infarct size  Infarct size (mm3)         
Ottani, A  2003  Infarct size  Infarct size (mm3)         
( 8.0.0.2542.854317350 PDF Extractor SDK EVALUATION)
Author  Year  Outcome Type  Outcome Measure 1  Outcome Measure 2 
Outcome 
Measure 3 
Outcome 
Measure 4 
Outcome 
Measure 5 
Neurobehavioural score 
Morris water maze latency 
(sec) 
Morris water maze time spent 
outside target quadrant (sec) 
Satoh, S  2010 
Infarct size  % of coronal half hemisphere         
Neurobehavioural score  Postural reflex test score   
Shirakura, T  2005  Infarct size  Infarct area (mm2)         
Takeo, S  2003 
Infarct size  Infarct area (mm2)         
Neurobehavioural score 
Neurological deficit score (10 
point scale) 
Morris water maze visible 
platform latency (sec) 
Takeo, S  2003  Neurobehavioural score 
Morris water maze latency 
(sec) 
Takeo, S  2003  Neurobehavioural score 
Morris water maze visible 
platform latency (sec) 
Toshima, Y  2000 
Infarct size  Infarct area (mm2)         
Neurobehavioural score 
Neurological deficit score (3 
point scale) 
Ueki, A  1993 
Infarct size  Infarct size (mm3)         
Neurobehavioural score 
Apomorphine-induced rotation 
peak (counts per 5 minutes) 
Apomorphine-induced rotation 
area under curve (counts per 5 
minutes) 
Whitehead, S  2005  Neurobehavoural score  Staircase test (pellets eaten) 
Staircase test contralateral 
paw to infarct (pellets eaten) 
Staircase test 
ipsilateral paw to 
infarct (pellets 
eaten) 
(EVAL PDF Extractor SDK 8.0.0.2542-502945459)
Study references
Amenta F, Strocchi P, Sabbatini M. Vascular and neuronal hypertensive brain damage: 
protective effect of treatment with nicardipine. J Hypertens Suppl. 1996;14:S29-S35. 
Ando T, Takagi N, Takagi K, Kago T, Takeo S. Effects of nefiracetam on the levels of brainderived
neurotrophic factor and synapsin I mRNA and protein in the hippocampus of 
microsphere-embolized rats. Eur J Pharmacol. 2005;507:49-56. 
Antonucci F, Cerri C, Maya Vetencourt JF, Caleo M. Acute neuroprotection by the synaptic 
blocker botulinum neurotoxin E in a rat model of focal cerebral ischaemia. 
Neuroscience. 2010;169:395-401. 
Date I, Takagi N, Takagi K, Kago T, Matsumoto K, Nakamura T, et al. Hepatocyte growth 
factor improved learning and memory dysfunction of microsphere-embolized rats. J 
Neurosci Res. 2004;78:442-453. 
Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Beneficial effects 
of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive 
rats. J Pharmacol Exp Ther. 2011;339:358-366. 
Fujita Y, Lin JX, Takahashi R, Tomimoto H. Cilostazol alleviates cerebral small-vessel 
pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats. 
Brain Res. 2008;1203:170-176. 
Fuxe K, Kurosawa N, Cintra A, Hallström A, Goiny M, Rosén L, et al. Involvement of local 
ischemia in endothelin-1 induced lesions of the neostriatum of the anaesthetized rat. 
Exp Brain Res. 1992;88:131-139. 
Giuliani D, Ottani A, Mioni C, Bazzani C, Galantucci M, Minutoli L, et al. Neuroprotection in 
focal cerebral ischemia owing to delayed treatment with melanocortins. Eur J 
Pharmacol. 2007;570:57-65. 
Han F, Shirasaki Y, Fukunaga K. 3-[2-[4-(3-Chloro-2-methylphenylmethyl)-1-
piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydro-chloride 
3.5 hydrate (DY-9760e) is neuroprotective in rat microsphere embolism: role of the 
cross-talk between calpain and caspase-3 through calpastatin. J Pharmacol Exp Ther. 
2006;317:529-536. 
Hayashi A, Suzuki M, Ogawa Y, Sonoda R, Sasamata M. Post-stroke atorvastatin treatment 
reduces neurological deficits and mortality rate in the stroke-prone spontaneously 
hypertensive rat. J Pharm Pharmacol. 2004;56:893-898. 
Hewlett KA, Corbett D. Delayed minocycline treatment reduces long-term functional deficits 
and histological injury in a rodent model of focal ischemia. Neuroscience. 2006;141:27-
33. 
Horie N, Maag AL, Hamilton SA, Shichinohe H, Bliss TM, Steinberg GK. Mouse model of 
focal cerebral ischemia using endothelin-1. J Neurosci Methods. 2008;173:286-290. 
Hua R, Walz W. Minocycline treatment prevents cavitation in rats after a cortical 
devascularizing lesion. Brain Res. 2006;1090:172-181. 
Huang JL, Fu ST, Jiang YY, Cao YB, Guo ML, Wang Y, et al. Protective effects of 
Nicotiflorin on reducing memory dysfunction, energy metabolism failure and oxidative 
stress in multi-infarct dementia model rats. Pharmacol Biochem Behav. 2007;86:741-
748. 
Imamura T, Kiguchi S, Kobayashi K, Ichikawa K, Yamazaki Y, Kojima M. Effect of ozagrel, a 
selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. 
Comparative study with norphenazone, a free-radical scavenger. 
Arzneimittelforschung. 2003;53:688-694. 
( 8.0.0.2542.922101496 PDF Extractor SDK EVAL VERSION)
Ishizuka T, Niwa A, Tabuchi M, Nagatani Y, Ooshima K, Higashino H. Involvement of 
thromboxane A2 receptor in the cerebrovascular damage of salt-loaded, stroke-prone 
rats. J Hypertens. 2007;25:861-870. 
Lapchak PA. The phenylpropanoid micronutrient chlorogenic acid improves clinical rating 
scores in rabbits following multiple infarct ischemic strokes: synergism with tissue 
plasminogen activator. Exp Neurol. 2007;205:407-413. 
Lapchak PA. Efficacy and safety profile of the carotenoid trans sodium crocetinate 
administered to rabbits following multiple infarct ischemic strokes: a combination 
therapy study with tissue plasminogen activator. Brain Res. 2010;1309:136-145. 
Lapchak PA, Araujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: a novel 
thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke. 
2002;33:2279-2284. 
Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA. Neuroprotective effects of the spin trap 
agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic 
NXY-059) in a rabbit small clot embolic stroke model: combination studies with the 
thrombolytic tissue plasminogen activator. Stroke. 2002;33:1411-1415. 
Lapchak PA, Araujo DM, Zivin JA. Comparison of Tenecteplase with Alteplase on clinical 
rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185:154-
159. 
Lapchak PA, Han MK. Simvastatin improves clinical scores in a rabbit multiple infarct 
ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue 
plasminogen activator. Brain Res. 2010;1344:217-225. 
Lapchak PA, Maher P, Schubert D, Zivin JA. Baicalein, an antioxidant 12/15-lipoxygenase 
inhibitor improves clinical rating scores following multiple infarct embolic strokes. 
Neuroscience. 2007;150:585-591. 
Lapchak PA, Song D, Wei J, Zivin JA. Coadministration of NXY-059 and tenecteplase six 
hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol. 
2004;188:279-285. 
Lapchak PA, Song D, Wei J, Zivin JA. Pharmacology of caffeinol in embolized rabbits: 
clinical rating scores and intracerebral hemorrhage incidence. Exp Neurol. 
2004;188:286-291. 
Lapchak PA, Wei J, Zivin JA. Transcranial infrared laser therapy improves clinical rating 
scores after embolic strokes in rabbits. Stroke. 2004;35:1985-1988. 
Lapchak PA, Zivin JA. Ebselen, a seleno-organic antioxidant, is neuroprotective after 
embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. 
Stroke. 2003;34:2013-2018. 
Lapchak PA, Zivin JA. The lipophilic multifunctional antioxidant edaravone (radicut) improves 
behavior following embolic strokes in rabbits: a combination therapy study with tissue 
plasminogen activator. Exp Neurol. 2009;215:95-100.
Lecrux C, McCabe C, Weir CJ, Gallagher L, Mullin J, Touzani O, et al. Effects of magnesium 
treatment in a model of internal capsule lesion in spontaneously hypertensive rats. 
Stroke. 2008;39:448-454. 
Miyake K, Takagi N, Takeo S. Effects of naftidrofuryl oxalate on microsphere embolisminduced
decrease in regional blood flow of rat brain. Br J Pharmacol. 1994;112:226-
230. 
Mochizuki N, Moriyama Y, Takagi N, Takeo S, Tanonaka K. Intravenous injection of neural 
progenitor cells improves cerebral ischemia-induced learning dysfunction. Biol Pharm 
Bull. 2011;34:260-265. 
(PDF Extractor SDK TRIAL VERSION)
Mochizuki N, Takagi N, Kurokawa K, Onozato C, Moriyama Y, Tanonaka K, et al. Injection of 
neural progenitor cells improved learning and memory dysfunction after cerebral 
ischemia. Exp Neurol. 2008;211:194-202. 
Nagakura A, Niimura M, Takeo S. Effects of a phosphodiesterase IV inhibitor rolipram on 
microsphere embolism-induced defects in memory function and cerebral cyclic AMP 
signal transduction system in rats. Br J Pharmacol. 2002;135:1783-1793. 
Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. 
Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously 
hypertensive rats, independently of blood pressure. Stroke. 2007;38:3016-3022. 
Oshikawa S, Miyake-Takagi K, Takagi N, Abe T, Kuruhara Y, Takeo S. Effects of 
monochlorobimane on cerebral ischemia-induced damage to mitochondria. Biol Pharm 
Bull. 2004;27:166-169. 
Ottani A, Giuliani D, Mioni C, Galantucci M, Minutoli L, Bitto A, et al. Vagus nerve mediates 
the protective effects of melanocortins against cerebral and systemic damage after 
ischemic stroke. J Cereb Blood Flow Metab. 2009;29:512-523. 
Ottani A, Saltini S, Bartiromo M, Zaffe D, Renzo Botticelli A, Ferrari A, et al. Effect of 
gamma-hydroxybutyrate in two rat models of focal cerebral damage. Brain Res. 
2003;986:181-190. 
Park L, Thornhill J. Phosphoramidon-sensitive endothelin-converting enzymes modulate 
cerebral blood flow and neural damage of hypoxic rats. Neurosci Lett. 2001;301:95-98. 
Roos MW, Ericsson A.. N-tert-butyl-alpha-phenylnitrone reduces the number of 
microinfarctions in the rabbit brain cortex. Exp Brain Res. 1999;124:271-272. 
Satoh S, Hitomi A, Ikegaki I, Kawasaki K, Nakazono O, Iwasaki M, et al. Amelioration of 
endothelial damage/dysfunction is a possible mechanism for the neuroprotective 
effects of Rho-kinase inhibitors against ischemic brain damage. Brain Res Bull. 
2010;81:191-195. 
Shinyama H, Nagai H, Kawamura T, Narita Y, Nakamura N, Kagitani Y. Therapeutic effects 
of AE0047, a novel calcium antagonist, on progression of brain damage after stroke in 
stroke-prone spontaneously hypertensive rats. Gen Pharmacol. 1998;30:379-386. 
Shirakura T, Han F, Shiota N, Moriguchi S, Kasahara J, Sato T, et al. Inhibition of nitric oxide 
production and protein tyrosine nitration contribute to neuroprotection by a novel 
calmodulin antagonist, DY-9760e, in the rat microsphere embolism. Biol Pharm Bull. 
2005;28:1658-1661. 
Takagi N, Miyake K, Ohiwa A, Nukaga R, Takeo S. Effects of delayed treatment with 
nafronyl oxalate on microsphere embolism-induced changes in monoamine levels of 
rat brain regions. Br J Pharmacol. 1996;118:33-40. 
Takeo S, Hayashi H, Miyake K, Takagi K, Tadokoro M, Takagi N, et al. Effects of delayed 
treatment with nebracetam on neurotransmitters in brain regions after microsphere 
embolism in rats. Br J Pharmacol. 1997;121:477-484.
Takeo S, Fukatsu T, Miyake-Takagi K, Takagi N, Niimura M, Nagakura A, et al. Persistent 
effects of delayed treatment with nefiracetam on the water maze task in rats with 
sustained cerebral ischemia. J Pharmacol Exp Ther. 2003;304:513-523. 
Takeo S, Miyake-Takagi K, Kikuchi K, Ando T, Ichikawa T, Omino K, et al. Effects of 
nefiracetam on cerebral adenylyl cyclase activity in rats with microsphere embolisminduced
memory dysfunction. Biol Pharm Bull. 2003;26:318-322. 
Takeo S, Niimura M, Miyake-Takagi K, Nagakura A, Fukatsu T, Ando T, et al. A possible 
mechanism for improvement by a cognition-enhancer nefiracetam of spatial memory 
(EVALUATION PDF Extractor SDK 8.0.0.2542.315673705)
function and cAMP-mediated signal transduction system in sustained cerebral 
ischaemia in rats. Br J Pharmacol. 2003;138:642-654. 
Tanaka N, Katayama Y, Katsumata T, Otori T, Nishiyama Y. Effects of long-term 
administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and 
local cerebral blood flow in stroke-prone spontaneously hypertensive rats. Brain Res. 
2007;1169:125-132. 
Toshima Y, Satoh S, Ikegaki I, Asano T. A new model of cerebral microthrombosis in rats 
and the neuroprotective effect of a Rho-kinase inhibitor. Stroke. 2000;31:2245-2250. 
Ueki A, Rosén L, Andbjer B, Agnati LF, Hallström A, Goiny M, et al. Evidence for a 
preventive action of the vigilance-promoting drug modafinil against striatal ischemic 
injury induced by endothelin-1 in the rat. Exp Brain Res. 1993;96:89-99. 
Ueno H, Hara T, Ishi A, Shuto K. Effects of benidipine hydrochloride on cerebrovascular 
lesions in salt-loaded stroke-prone spontaneously hypertensive rats: evaluation by 
magnetic resonance imaging. Jpn J Pharmacol. 2000;84:56-62. 
Wengenmayer C, Krikov M, Mueller S, Lucht K, Villringer A, Hocher B, et al. Novel therapy 
approach in primary stroke prevention: simultaneous inhibition of endothelin converting 
enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats 
improves survival. Neurol Res. 2011;33:201-207. 
Whitehead S, Cheng G, Hachinski V, Cechetto DF. Interaction between a rat model of 
cerebral ischemia and beta-amyloid toxicity: II. Effects of triflusal. Stroke. 
2005;36:1782-1789. 
Whitehead SN, Massoni E, Cheng G, Hachinski VC, Cimino M, Balduini W, et al. Triflusal 
reduces cerebral ischemia induced inflammation in a combined mouse model of 
Alzheimer's disease and stroke. Brain Res. 2010;1366:246-256. 
Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator 
reduces neurological damage after cerebral embolism. Science. 1985;230:1289-129.
(TRIAL PDF Extractor SDK 8.0.0.2542-2111785461)
54
（Stroke 2014, 45:563-570. 上海仁济医院神经内科林 岩 译； 李焰生 校）
Basic Sciences
干预措施的系统回顾及荟萃分析
对腔隙性卒中动物模型
Systematic review and meta-analysis 
of interventions tested in animal models of lacunar stroke
Peddor H, Vesterinen HM, Macleod MR, Wardlaw JM
背景和目的：25% 的卒中为腔隙性卒中，它在病理生理学上与大动脉性卒中完全不同。尽管不断出现的证据显示其对躯体残疾和
痴呆有相当的影响，但对其特异性治疗的关注却很少。如何最优化使用腔隙性卒中动物模型以检测某些干预措施，尚不清楚。
方法：我们对在腔隙性卒中动物模型中检测干预措施的研究进行了系统回顾和荟萃分析，使用随机 - 效应荟萃分析方法评估研究特
征的影响并寻找发表偏倚的证据。
结果：57 篇文献描述了 43 项不同干预措施的疗效。在总分 8 分的研究质量评分列表中，中位数是 3 分（四分位范围，2-4）。
许多模型表现的发病机制与腔隙性卒中相关性很小。对 27 项研究结果的荟萃分析显示，梗死体积和神经行为结局分别平均提高
34.2%（24.1 ～ 44.2），平均标准差 0.82（0.51 ～ 1.14）。4 项干预措施能同时改善了梗死体积和神经行为结局，但缺乏充足
的数据证明这些发现具有足够的说服力。在梗死面积方面，盲法研究中的疗效较低，随机研究中的疗效较高。在神经行为方面，随
机研究中的疗效偏低。在梗死面积上，存在发表偏倚。
结论：尚无任何干预措施在足够广度和深度上可以转化到临床试验。仅有限的报道中治疗措施减少了偏倚风险，证据存在大量发表
偏倚。
关键词：荟萃分析，系统性综述，腔隙性卒中
腔隙性卒中是单支穿支动脉闭塞所致的皮层下小卒中。血栓栓塞
是大动脉性卒中的常见原因，腔隙性卒中假设，虽备受争议，认为腔
隙病理的关键机制是微粥样硬化瘤和脂质透明变，而血栓栓塞性腔隙
性卒中少见。微粥样硬化瘤是富含脂质的斑块，沉积在颅内主要大动
脉（如大脑中动脉）并累及穿支动脉的起始处，抑或是形成于穿支小
动脉的近端。脂质透明样变是小血管的病理改变，特征是内皮细胞结
构异常和纤维化，导致血管壁增厚和腔径不规则。尽管与内皮细胞炎
性功能异常及血脑屏障破坏有关，这些小血管改变的原因还不清楚。
25% 的缺血性卒中为腔隙性，虽然看似其功能结局较皮质性缺血
性卒中好，但也有类似比例的患者会发生卒中后认知功能障碍，而且
长期的研究提示，脑小血管病（small vessel disease, SVD）增加患
者缺血性卒中复发和认知功能下降的风险。
然而，导致上述病理改变的确切机制还不完全了解，目前的治疗
策略也很有限。这反映了转化医学失败的大背景，许多在缺血性卒中
动物模型能改善预后的措施在人类临床试验中均无效。 
可能动物模型不能充分有效地模拟人类疾病以指导药物研发，也
可能动物模型是有效的，但实验操作和报道误导了临床药物的开发或
试验设计。对于神经系统疾病的数个动物模型，结合不同研究数据进
行系统回顾和荟萃分析，能对研究的设计及质量的影响提供一些有用
的思考。在此，我们评估了不同治疗对腔隙性卒中动物模型行为和结
构结局疗效的相关证据，尤其集中在减少偏移的治疗措施报道，以及
发表偏移的可能性上。
方法
研 究 方 案 见 www.camarades.info/index_files/protocols.
htm，研究方法的细节由 Vesterinen 等提供。
检索策略
我们于 2012 年 3 月 6 日检索了 Medline（自 1950）、ISI 科学
网站（自 1969）和 EMBASE（自 1980）数据库，检索了腔隙性卒
中动物模型的相关研究（包括但不仅限于干预性研究）。此外，我们
检索了以前腔隙性卒中动物模型的系统回顾所引用的原始研究文献。
没有语言限制。 
入选和排除标准
我们入选了暴露于腔隙性卒中（定义为推测由穿支血管闭塞、狭
窄或其他疾病所导致的局灶性皮质下区域性缺血性损伤）损伤动物模
型的实验以及有对照的干预性队列动物结局研究。入选的研究应量化
结构性（损伤体积）和功能性（行为）结局。排除单个病灶 >1/140 大
脑总容积的研究，也排除由非单个血管机制（如外伤性脑损伤）、出血、
部分性或完全性的大脑中动脉或颈总动脉闭塞所致病变的研究；排除
转基因研究和模拟新生动物的缺氧 / 缺血研究；排除干预措施用于恶化
而非改善结局的研究。
数据提取
记录作者、发表年份、干预措施和剂量、动物种类（包括物种、
类型和性别）、干预类型、干预时间和结局评估时间、结局评估方法、
平均结局、SD 或 SE、每组动物数量、使用盐负荷、卒中诱导方法、
麻醉使用、研究质量评估参数和避免偏倚措施的报告（见下）。
定义治疗比较为比较了对照组和治疗组动物的结局。对使用自发
性高血压卒中易感大鼠（SHRSPs）的研究，我们没有记录给药时间或
结局评估，原因是没有卒中诱发的确切时间点。当给予 >1 个干预措施
时，我们认为这种联合是种独特和单一的干预措施。当治疗为多次给
(EVAL PDF Extractor SDK 8.0.0.2542-383457851)
55
药时，我们认定治疗为首剂时间，剂量为头 24 小时的剂量总和。当报
道的数据来自多个脑切片时，我们仅入选对照组梗死最大对应的切片。
当报道的神经行为结局 >1 个时间点时，我们仅入选最晚时间评估作为
临床最相关的终点。当数据以图表表示时，我们与作者联系寻找进一
步信息，如果需要从图表上测量数值。
质量评估
使用实验性研究中动物数据荟萃分析和系统回顾的协作方法
（CAMARADES）列表 10 项中的 8 项来评估偏倚风险。未包括温度
控制和避免使用具有明显内在特性的麻醉剂的陈述，因为我们认为这
些与腔隙性卒中模型的相关性很小。我们记录所选研究：①是否发表
于同行评审杂志，及在哪儿发表；②试验是否随机分组；③实验期间
是否保持盲法分组；④是否盲法评估结局；⑤实验动物是否有相关合
并症；⑥是否有样本量计算的陈述；⑦是否有遵循管理要求的陈述；
⑧是否有可能利益冲突的陈述。
数据分析（略）
结果
研究特征
我们电子搜索找到 4379 篇文献，其中 4322 篇排除，剩余 57 篇
入选系统回顾。
关于腔隙性卒中的诱发方法，57 项研究中，16 项（28%）为经
颈内动脉微血栓注射，15 项（25%）为经颈内动脉微球注射，12 项
（21%）为深部灰质注射内皮素。有 5 项研究（9%）应用了盐负荷加
速 SHRSP 的自发卒中和无盐负荷 SHRSP 自发性卒中。所有研究中，
41 项（72%）使用大鼠，其余为兔或小鼠。仅 47 项研究报道在诱导卒
中过程中使用麻醉剂。
所有研究，按照总分 8 分的研究质量列表项评分的中位数为 3（四
分位间距，2-4）。所有研究均发表在同行评审的杂志上。57 项研究中，
26 项（46%）报道随机分配，10 项（18%）报道实验中盲法分组，26
项（46%）报道盲法评估结局，12项（21%）报道使用相关共病（高血压）
动物，7 项（12%）声明可能的利益冲突，5 项（9%）（来自同一实
验室的研究）报道样本量计算，44 项（77%）陈述了遵循动物管理要求。
荟萃分析
16 篇文献的数据无法收入荟萃分析，因为诸如方差、在涉及损伤
大小时非损伤动物的数据等关键信息没有报道或无法推测。13 篇文献
报道了大量微血凝块在 50% 的动物中产生神经功能障碍。虽然完全符
合腔隙性卒中的模型，但是没有提供适合荟萃分析的数据，所以被排除。
剩余 27 篇文献描述了 67 项实验方法，涉及 1099 只动物，22 种药物
的功效；其中涉及 736 只动物的 37 项实验报道了神经行为改变，涉及
422 只动物的 30 项研究报道了梗死体积。
疗效
总体上，在检验18种干预措施的实验中，神经行为评分改善了0.82
个 SMD（95% CI 为 0.51 ～ 1.14，37 项比较，736 只动物），研究间
的异质性巨大（χ2=170.3，I2=79%，df=36，P<0.0057）。干预措施
分层分析显示，18 种措施中 8 种显著改善结局（χ2=128.4，df=17，
P<0.0057，见图 1A）。
梗死体积在检验 18 种干预措施的实验中改善了 34.3（95% CI 为 
24.2% ～ 44.4%，30 项比较，422 只动物），研究间的异质性同样巨
大（ χ 2=91.0，I2=68%， df=29，P<0.0057）。干预措施分层分析显示，
18 种措施中 8 种显著改善结局（χ2=83.1，df=17，P<0.0057，见
图 1B）。
4 项干预措施同时改善了神经行为预后和梗死体积：丙克拉默
（preclamol）（1 篇文献，68 只动物，研究质量评分 4 分）；法舒
地尔（1篇文献，44只动物，研究质量评分2分） ；烟花甙（nicotiflorin）
（1 篇文献，48 只动物，研究质量评分 4 分）；肝细胞生长因子（1
篇文献，21 只动物，研究质量评分 2 分）。其他化合物改善了神经行
为（DY9760e、阿托伐他汀、羟基法舒地尔、奥扎格雷）或梗死体积
（双肼酞嗪、神经前体细胞、γ- 羟基丁酸、西洛他唑、莫达非尼、二
甲胺四环素），但非同时改善，虽然这其中有 4 种报道了神经行为（阿
托伐他汀、奥扎格雷）或梗死体积（双肼酞嗪、西洛他唑）。
研究质量
关于神经行为评分，随机状态而非盲法状态的分层研究，解释了
相当部分的观察到的异质性（图 2A）。非随机化相对增加了报道的功
效282%（95% CI为17%～546%，见图 2C）。盲法[相对减少功效8%
（95%CI 为 -110% ～ 94%）] 或使用相关共病动物（见图 2C）没有
图 1. 使用标准化平均差（SMDs；A）计算的 18 项干预措施的神经行为评分和使用归一化平均差计算的 18 种干预措施梗死体积改善（B）的森林图。
水平误差短线代表 95% 置信区间（CI）。垂直灰色条代表总体疗效的 95%CI。图形大小代表每个干预措施实验的动物相对数目。NDP-a-MSH
表示 [Nle(4), D-Phe(7)]-<alpha>- 促黑激素；PPP 表示（3-(3- 羟苯基 )-N-n- 丙基哌啶）。
Pedder et al    Interventions in Animal Models of Lacunar Stroke
(TRIAL VER. PDF Extractor SDK 8.0.0.2542.1685538491)
56
对功效产生明显的影响。
关于梗死体积，随机或盲法状态的分层研究均解释了观察到的
相当比例的异质性（见图 2B），非随机化使疗效相对减少25.5%
（95%CI 为 -84.3% ～ 33.1%），非盲法使疗效相对增加 28.4%（95%CI
为 -60% ～ 116%，见图 2C）。动物是否有合并症没有明显的差异。
总体而言，研究质量列表评分的得分解释了相当部分观察到的异质性，
不论是神经行为（χ2=21.0，df=4，P<0.0057，见图 3A）或是梗死
体积（χ2=44.3，df=5，P<0.0057，见图 3B），最高质量的研究给出
了疗效的最低估计值。
发表偏倚
漏斗图显示神经行为结局（见图 4A）的明显不对称，而梗死体积
则不然（间图 4B），但是 Egger 回归提示均有发表偏倚（见图 4C 和
4D）。运用整理和填充分析，估计 20 项未发表的神经行为结局（见图
4A）给出校正的总体功效为 0.13SMD（95%CI 为 -0.13 ～ 0.55），
相 较 于 1.04SMD（95%CI 为 0.67 ～ 1.40）。 梗 死 体 积 上， 估 计 2
项未发表研究（见图 4B）会轻度减少总体功效从 33.9%（95%CI 为
24.4 ～ 43.3）到 33.0%（95%CI 为 24.4 ～ 42.4）。
研究特征
关于神经行为评分，腹腔内给药最有效（1.62 SMD，95%CI
为 0.90 ～ 2.34）， 纹 状 体 内 给 药 效 果 最 差（(-0.15 SMD，95% 
CI 为 -0.66 ～ 0.37，Χ2=31.3，df=6，P<0.0057， 见 图 5A）。 使 用
SHRSP 的自发性卒中的研究报道的功效最高（1.56 SMD， 95% 
CI 为 0.60 ～ 2.52）， 使 用 微 球 的 功 效 最 低（0.50 SMD，95% CI
为 –0.02 ～ 1.02，Χ2=23.3，df=4，P<0.0057， 见 图 5B）。 卒 中
后1周内评估结局的研究报道的功效最高（1.12 SMD，95% CI为
0.58 ～ 1.65）。评估时间越短，则功效越低，那些卒中后 >1 月进行结
局评估的研究均未见显著改善（-0.06 SMD，95% CI 为 -0.60 ～ 0.48；
Χ2=18.7，df=4，P<0.0057，见图 5C）。未见明显的治疗时间的影响。
关于梗死体积，在卒中发病 3 小时后给药功效差（20.8%，95% CI
为 6.8 ～ 34.7），不及 3 小时内给药（37.4%，95% CI 为 20.0 ～ 54.9）
或 发 病 前 给 药（43.6%，95% CI 为 17.1 ～ 70.1，Χ2=22.1，df=3，
P<0.0057，见图 6A）。卒中后 1 ～ 3 周进行结局评估者，功效显著低
于其他时间（14.1%，95% CI 为 -4.7 ～ 32.8），在首周内评估结局的
研究的功效最高（43.3%，95% CI 为 20.9 ～ 65.8，Χ2=42.4，df=2，
P<0.0057，见图 6B）。未见卒中诱导方法及途径有显著影响。
图 2. 研究报告随机化对下列各方面的显著影响：A：对神经行为，使用标准化平均差计算；B：对梗死体积，使用归一化平均差计算。报告盲法对下
列各方面的影响：B：对梗死体积有显著影响；A：对神经行为评分无明显影响。垂直误差短线表示 95% 置信区间（CI）。水平灰色条表示总体疗
效的 95%CI。条图的宽度表示每个比较中动物的相对数目。非随机和非盲法研究中，报道的对神经行为评分和梗死体积疗效的相对变化见 C。
Stroke    February 2014
(EVAL PDF Extractor SDK 8.0.0.2542-189095164)
57
图 3.  随研究质量评分的上升，对下列方面的影响：A：对神经行为结局的疗效下降，使用标准平均差（SMDs；A）计算；B：对梗死体积的疗效下降，
使用归一化平均差计算。垂直误差短线表示 95% 置信区间（CI）。水平灰色条表示总体疗效的 95%CI。条图宽度表示每个比较中动物的相对数目。
图 4. 使用 Trim and Fill 分析对发表结局（黑圈）和未发表结局研究（灰圈）估算的神经行为（A）和梗死体积（B）疗效的漏斗图。垂直灰线表示
总体功效。Egger 回归图为神经行为（C）和梗死体积（D）的回归线及 95% 置信区间。
疗效大小（SMD）
精确度（1/SE）
疗效大小（%）
疗效大小/标准差 疗效大小/标准差
精确度（1/SE）
精确度（1/SE） 精确度（1/SE）
Pedder et al    Interventions in Animal Models of Lacunar Stroke
(PDF Extractor SDK TRIAL VERSION)
58
图 5. 常规给药（A）、卒中诱导方法（B）和结局评估时间（C）对神经行为评分的显著影响，使用标准平均差（SMDs）计算。垂直误差短线表示
95% 置信区间（CI），水平灰色条表示总体疗效的 95%CI。条图宽度表示每个比较中动物的相对数目。
图 6. 给药时间（A）和评估时间（B）对梗死体积的显著影响，使用归一化平均差计算。垂直误差短线表示 95% 置信区间（CI），水平灰色条表示
总体疗效的 95%CI。条图宽度表示每个比较中动物的相对数目。
Stroke    February 2014
( 8.0.0.2542.301491839 PDF Extractor SDK EVALUATION)
59
讨论
我们报道了在 7 种独立的腔隙性脑卒中动物模型中检验的 22 种干
预措施的荟萃分析结果。14 种措施改善梗死体积和（或）神经行为结
局，其中 10 种已经获得美国食品药品监督管理局批准用于其它适应症
治疗。然而，减少偏倚措施的使用水平很低妨碍了数据的内在可靠性，
发表偏倚的可能性又妨碍了外延的可靠性。这些不足提示，即使是看
似有前景的干预措施，在开始临床试验前仍然需要进一步高质量的相
关模型的有效数据，特别是新的干预措施。
可能的不足
本研究为观察性，分析了既往收集的数据，研究发现仅是用于产
生假设。可能观察到的差异是由一些与感兴趣变量共分离的因素所致，
数据集太小以致不能做多因素分析。我们无法从 11 篇发表文献中获取
数据。因为低质量的研究夸大了功效，而我们入选了所有研究，这将
会夸大治疗效应。许多实验模型反映的机制与多数无关。最与人类腔
隙性卒中相关的模型是 SHRSP，由于缺乏卒中发病时间而未能入选。
疗效
4 项干预同时改善神经行为结局和梗死体积，其中仅法舒地尔有过
临床试验，初步结果不错。其他一些措施经检验可以改善 1 项结局。
对于局灶性缺血，虽然合并了约 1000 只动物的数据显示出稳定的功效，
我们认为还需要更多更好的动物模型的疗效证据来帮助设计临床试验。
偏倚风险
虽然避免偏倚治疗措施的报告较少，但与卒中及其他神经疾病的
系统性回顾仍有可比性。报道几项治疗措施避免偏倚的研究却显示了
治疗效果最好。非随机研究中报道对神经行为结局的疗效夸大，与以
前的发现一致。虽然根据随机或盲法情况对梗死体积的分层解释了观
察到的很大比例的异质性，但在其他方面的分层还是不同的，例如，
随机研究中开始治疗的中位时间非常短。除了随机状态和神经行为评
分，在有偏倚风险的研究中，疗效差异的 95% 置信区间包含零。在报
道了神经行为结局和梗死体积的实验间，非随机化影响的差异，既可
能是因其他变量的混淆效应，也可能确实存在差异，来源于非随机分
组基线时神经行为完成能力的差异。我们认为小的研究影响的证据，
特别是神经行为结局方面，反映了发表偏倚，支持对此应建立解决该
问题的系统。
腔隙性卒中模型使用不同的损伤，还不清楚是否存在一个最好的
模型，或不同模型是否适合不同的研究问题。血栓栓塞是人类腔隙性卒
中的少见原因，但超过半数的研究使用栓塞模型。这明显限制了所报
数据的临床相关性，也强调了使用相关性更好的已有模型和建立更好
的腔隙性卒中模型的重要性。SHRSP 的自发性卒中可能最类似于人类
腔隙性卒中，所以关注该模型可能更有意义。未来试验设计应关注自
发性腔隙性卒中模型中卒中发生时间的评估。腔隙性卒中患者的脑损
害通常不局限于卒中影响的脑组织，更多的是它的多样性，因为 SVD
具有弥散性。因此，像 SHRSP 这样的广泛性脑损害模型，似乎与药物
试验更相关，因为它能模拟从卒中事件的恢复以及对 SVD 等其他脑血
管病事件的效应。
在模型合适、时间恰当和偏倚风险低的实验中，即使有对结局小
的改善，都能对开展临床试验提供有效的证据。然而，要使研究具有
充分效力，需要进行更大样本量，而且需要通过多中心的动物实验完成。
Pedder et al    Interventions in Animal Models of Lacunar Stroke
基于循证的临床试验设计
腔隙性卒中是 SVD 领域的一部分。表现为急性腔隙性卒中综合征
的患者可能应立即开始治疗以预防腔隙性卒中的复发。然而，SVD 的
其他表现则是典型的静息性累积，患者除非发生认知功能或躯体功能衰
退，否则不会治疗，然而在此阶段治疗的功效可能已经下降。治疗防
止腔隙性卒中进展是有益的，但仅有4项研究验证了卒中前治疗的疗效。
理想的治疗应该既能长期地预防临床急性腔隙性卒中综合征的复发，
又能预防 SVD 静息性特征的增加。换言之，既对神经行为结局的影响
似乎不会随时间而下降，又对结构性结局的任何影响能有所增加。
结论
我们的发现为进一步实验室和临床研究提供了参考。首先，最适
合用于验证干预措施的腔隙性卒中的动物模型还不明确，而目前最相
关的模型还存在实验设计问题，诸如如何识别新发卒中及确定发病时
间。其次，提高研究的内在（研究质量）和外在（发表偏倚）有效性
可为向临床试验转化提供坚实基础，更进一步探索这些研究有效性的
局限方面能够为入选和排除这类试验的标准提供启示。 
参考文献
1.Bamford JM, Warlow CP. Evolution and testing of the lacunar hypothesis.
Stroke. 1988;19:1074–1082.
2. Millikan C, Futrell N. The fallacy of the lacune hypothesis. 
Stroke.1990;21:1251–1257.
3. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic 
cerebralsmall vessel disease: insights from neuroimaging. Lancet 
Neurol.2013;12:483–497.
4. Del Bene A, Makin SDJ, Doubal FN, Inzitari D, Wardlaw JM. Variation 
in risk factors for recent small subcortical infarcts with infarct size,shape, 
and location. Stroke. 2013;44:3000–3006.
5. Fisher CM. Lacunar infarcts—a review. Cerebrovasc Dis.1991;1:311–320.
6. Knottnerus IL, Ten Cate H, Lodder J, Kessels F, van Oostenbrugge RJ. 
Endothelial dysfunction in lacunar stroke: a systematic review. Cerebrovasc 
Dis. 2009;27:519–526.
7. Giwa MO, Williams J, Elderfield K, Jiwa NS, Bridges LR, Kalaria RN, 
et al. Neuropathologic evidence of endothelial changes in cerebral small 
vessel disease. Neurology. 2012;78:167–174.
8. Sacco S, Marini C, Totaro R, Russo T, Cerone D, Carolei A. A 
population-based study of the incidence and prognosis of lacunar stroke. 
Neurology. 2006;66:1335–1338.
9. Norrving B. Long-term prognosis after lacunar infarction. Lancet Neurol. 
2003;2:238–245.
10. Garde E, Mortensen EL, Krabbe K, Rostrup E, Larsson HB. 
Relation between age-related decline in intelligence and cerebral whitematter
hyperintensities in healthy octogenarians: a longitudinal study. 
Lancet.2000;356:628–634.
11. Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten EC, 
van der Flier WM, et al; LADIS Study Group. Incident lacunes influence 
cognitive decline: the LADIS study. Neurology. 2011;76:1872–1878.
12. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, 
O’Collins V, et al. Can animal models of disease reliably inform human 
studies?PLoS Med. 2010;7:e1000245.
13. Sena E, van der Worp HB, Howells D, Macleod M. How can we 
improve the pre-clinical development of drugs for stroke? Trends Neurosci.
2007;30:433–439.
14. Vesterinen HM, Sena ES, ffrench-Constant C, Williams A, Chandran S,
Macleod MR. Improving the translational hit of experimental treatments
in multiple sclerosis. Mult Scler. 2010;16:1044–1055.
(8.0.0.2542.720647876 PDF Extractor SDK TRIAL VERSIOn)
